Lack of Benefit of Fluvoxamine for COVID-19

Adarsh Bhimraj; Jason C. Gallagher

doi:10.1001/jama.2022.23954

Lack of Benefit of Fluvoxamine for COVID-19

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	291-292
Number of pages	2
Journal	JAMA: The Journal of the American Medical Association
Volume	329
Issue number	4
DOIs	https://doi.org/10.1001/jama.2022.23954
State	Published - Jan 24 2023

ASJC Scopus subject areas

General Medicine

Divisions

Infectious Disease

Access to Document

10.1001/jama.2022.23954

Cite this

@article{25989280841b4e4a909a79bfb1dc31c4,

title = "Lack of Benefit of Fluvoxamine for COVID-19",

author = "Adarsh Bhimraj and Gallagher, \{Jason C.\}",

year = "2023",

month = jan,

day = "24",

doi = "10.1001/jama.2022.23954",

language = "English (US)",

volume = "329",

pages = "291--292",

journal = "JAMA: The Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - Lack of Benefit of Fluvoxamine for COVID-19

AU - Bhimraj, Adarsh

AU - Gallagher, Jason C.

PY - 2023/1/24

Y1 - 2023/1/24

UR - https://www.scopus.com/pages/publications/85147047841

UR - https://www.scopus.com/inward/citedby.url?scp=85147047841&partnerID=8YFLogxK

U2 - 10.1001/jama.2022.23954

DO - 10.1001/jama.2022.23954

M3 - Comment/debate

C2 - 36633871

AN - SCOPUS:85147047841

SN - 0098-7484

VL - 329

SP - 291

EP - 292

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 4

ER -

Lack of Benefit of Fluvoxamine for COVID-19

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Cite this